Sentiment for Islet Sciences Inc (NASDAQ:ONCE)
Islet Sciences Inc (NASDAQ:ONCE) institutional sentiment is 1.19 in 2018 Q2. Its the same as in 2018Q1. The ratio is without change, as only 75 funds opened new or increased positions, while 63 trimmed and sold stock positions in Islet Sciences Inc. The funds in our partner’s database now possess: 37.08 million shares, up from 36.74 million shares in 2018Q1. Also, the number of funds holding Islet Sciences Inc in their top 10 positions decreased from 2 to 1 for a decrease of 1. Sold All: 17 Reduced: 46 Increased: 51 New Position: 24.
Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. The company has market cap of $1.54 billion. The Company’s products include voretigene neparvovec, which is in Phase III clinical trial for the treatment of genetic blinding conditions called inherited retinal diseases caused by non sex-linked, autosomal recessive, or biallelic mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia. It currently has negative earnings. The companyÂ’s products also comprise SPK-7001 that is in Phase 1/2 trial for choroideremia; SPK-9001, which is in Phase 1/2 trial for hemophilia B; and SPK-8011 that is in Phase 1/2 trial hemophilia A.
The stock decreased 4.34% or $1.85 during the last trading session, reaching $40.82. About 474,228 shares traded. Spark Therapeutics, Inc. (NASDAQ:ONCE) has declined 28.27% since November 14, 2017 and is downtrending. It has underperformed by 43.89% the S&P500.
Great Point Partners Llc holds 5.73% of its portfolio in Spark Therapeutics, Inc. for 500,000 shares. Rock Springs Capital Management Lp owns 544,000 shares or 1.73% of their US portfolio. Moreover, Rhenman & Partners Asset Management Ab has 1.5% invested in the company for 177,600 shares. The California-based Partner Fund Management L.P. has invested 1.14% in the stock. Baker Bros. Advisors Lp, a New York-based fund reported 1.38 million shares.
Spark Therapeutics, Inc. (NASDAQ:ONCE) Ratings Coverage
Ratings analysis reveals 50% of Spark Therapeutics’s analysts are positive. Out of 10 Wall Street analysts rating Spark Therapeutics, 5 give it “Buy”, 1 “Sell” rating, while 4 recommend “Hold”. The lowest target is $40 while the high is $10300. The stock’s average target of $78 is 91.08% above today’s ($40.82) share price. ONCE was included in 13 notes of analysts from May 22, 2018. The stock of Spark Therapeutics, Inc. (NASDAQ:ONCE) earned “Sector Perform” rating by RBC Capital Markets on Thursday, July 19. BMO Capital Markets downgraded the shares of ONCE in report on Wednesday, August 8 to “Market Perform” rating. As per Monday, June 25, the company rating was maintained by BMO Capital Markets. The stock of Spark Therapeutics, Inc. (NASDAQ:ONCE) has “Strong Buy” rating given on Wednesday, November 7 by Raymond James. As per Wednesday, November 7, the company rating was upgraded by Wedbush. Credit Suisse maintained Spark Therapeutics, Inc. (NASDAQ:ONCE) rating on Monday, July 9. Credit Suisse has “Outperform” rating and $98 target. The stock of Spark Therapeutics, Inc. (NASDAQ:ONCE) has “Underperform” rating given on Tuesday, August 7 by Credit Suisse. The stock of Spark Therapeutics, Inc. (NASDAQ:ONCE) has “Buy” rating given on Wednesday, November 7 by FBR Capital. The rating was maintained by UBS on Wednesday, August 8 with “Neutral”. On Wednesday, August 8 the stock rating was maintained by Barclays Capital with “Overweight”.
More notable recent Spark Therapeutics, Inc. (NASDAQ:ONCE) news were published by: Seekingalpha.com which released: “Spark Therapeutics, Inc. (ONCE) CEO Jeffrey Marrazzo on Q3 2018 Results – Earnings Call Transcript” on November 06, 2018, also Marketwatch.com with their article: “Sangamo stock drops after JP Morgan downgrade” published on November 14, 2018, Nasdaq.com published: “Spark Therapeutics Reports Third Quarter 2018 Financial Results and Recent Business Progress” on November 06, 2018. More interesting news about Spark Therapeutics, Inc. (NASDAQ:ONCE) were released by: Nasdaq.com and their article: “Detailed Research: Economic Perspectives on Cerus, AdvanSix, Spark Therapeutics, Imperva, Central Garden & Pet …” published on October 18, 2018 as well as Seekingalpha.com‘s news article titled: “Spark Therapeutics 2018 Q3 – Results – Earnings Call Slides” with publication date: November 06, 2018.